CorMedix Inc. (CRMD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

25/25

Growth 5 Margin 5 Expansion 5 Platform 5 Financial 5

latest quarter score

Earnings Reports

25
CorMedix (CRMD) Q2 2026: DefenCath Expands with New LDO Pilot, Adjusted EBITDA Soars 162%
August 17, 2026
20
CorMedix (CRMD) Q1 2026: Full-Year Revenue Guidance Raised by $25M as DefenCath Demand Outpaces Reimbursement Transition
May 14, 2026
14
CoreMedix (CRMD) Q4 2025: Malenta Acquisition Adds $37M, DefendCast Faces Price Reset in 2026
March 05, 2026
18
CoreMedix (CRMD) Q3 2025: Melinta Acquisition Adds $15.5M Revenue, Shifts Growth Profile
November 12, 2025
18
Core Medics (CRMD) Q2 2025: Malinta Deal Adds $125M Revenue, Unlocking Specialty Pharma Scale
August 07, 2025
18
CoreMedix (CRMD) Q1 2025: R&D Spend Jumps 281% as DefendCath Uptake Expands
July 06, 2025

Browse all companies